Dr. Paul Blunden reports

CVR MEDICAL ANNOUNCES CLOSING OF SECOND TRANCHE OF FINANCING

CVR Medical Corp. has closed the second tranche of its previously announced non-brokered private placement financing.

An aggregate of 1,935,427 units at a price of 30 cents per unit were issued in the second tranche for gross proceeds of $580,628.10. Dr. Paul Blunden, a director of CVR Medical since CVR Medical's inception, and also involved with the development of the CSS device from the beginning, participated in this closing with an investment of $299,828.10. Due to timing and logistical issues, CVR Medical was not able to accommodate all interested investors into the second tranche closing. As a result, CVR Medical will take the necessary steps to proceed with a third tranche immediately to accommodate such investors.

Proceeds from the financing will be used for continuing working capital requirements relating to the development and commercialization of the proprietary subsonic, infrasonic and low frequency sound wave analysis technology and diagnostic device designed to detect and measure carotid arterial disease, known as the CSS device.

Each unit consists of one common share of CVR Medical and one transferable common share purchase warrant. Each warrant is exercisable at a price of 36 cents until Sept. 21, 2023, provided that if on any 10 consecutive trading days at any time after Jan. 22, 2019, the daily closing price of the shares on the TSX Venture Exchange is at or greater than 50 cents, CVR Medical may provide notice to the holder of the early expiry and thereafter, the warrants will expire on the date that is 30 calendar days after the date of the notice.

In the second tranche closing, CVR Medical did not pay any finder's fees.

The shares and the warrants are subject to a hold period expiring Jan. 22, 2019. The financing remains subject to final acceptance of the TSX Venture Exchange.

About CVR Medical Corp.

CVR Medical is a health care company that operates in the medical device industry focused on the commercialization of its disruptive, proprietary CSS device. CVR is currently in pivotal clinical trials in preparation for its planned submission to the U.S. Food and Drug Administration.

We seek Safe Harbor.